Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen Co's revenue per share for the
three
months ended in Dec. 2025 was €0.34.
RemeGen Co's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.47.
During the past 12 months, the average Revenue Per Share Growth Rate of RemeGen Co was 91.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 59.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for RemeGen Co's Revenue per Share or its related term are showing as below:
FRA:REG'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.7 Med: 59.2 Max: 409.8
Current: 59.2
During the past 8 years, RemeGen Co's highest 3-Year average Revenue Per Share Growth Rate was 409.80% per year. The lowest was -1.70% per year. And the median was 59.20% per year.
FRA:REG's 3-Year Revenue Growth Rate is ranked better than 85.55% of 768
companies
in the Biotechnology industry
Industry Median: 3.35
vs FRA:REG: 59.20
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
RemeGen Co Revenue per Share Related Terms
RemeGen Co Revenue per Share Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, MRNA: Revenue per Share Comparison
For the Biotechnology subindustry, RemeGen Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where RemeGen Co's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
RemeGen Co's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Revenue per Share of €0.47 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #111 out of 768 companies in the Biotechnology industry, placing it in the top 14.5%.
Is RemeGen Co's Revenue per Share too high?
RemeGen Co's current Revenue per Share is €0.47. Based on the distribution chart, RemeGen Co ranks #111 out of 768 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #111 out of 768 companies for Revenue per Share. This places RemeGen Co in the top 15% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.35, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Revenue per Share is €0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €25.24, compared to a current price of €8.35 — trading 66.9% below its estimated fair value. The current Revenue per Share is €0.47. RemeGen Co's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Revenue per Share is €0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.35 is trading 66.9% below its estimated GF Value™ of €25.24.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Revenue per Share: €0.47
GF Value™: €25.24 vs. price of €8.35 (66.9% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
45GF Score
Get the complete analysis for FRA:REG
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
